DYN
Income statement / Annual
Last year (2024), Dyne Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Dyne Therapeutics, Inc.'s net income was -$317.42 M.
See Dyne Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$506.00 M |
$1.37 B |
$842.00 M |
| Cost of Revenue |
$0.00
|
$2.46 M
|
$3.35 M
|
$1.09 M
|
$700,000.00
|
$271,000.00
|
$24,000.00
|
$2.93 B
|
$2.28 B
|
$2.03 B
|
| Gross Profit |
$0.00
|
-$2.46 M
|
-$3.35 M
|
-$1.09 M
|
-$700,000.00
|
-$271,000.00
|
-$24,000.00
|
-$2.43 B
|
-$915.00 M
|
-$1.19 B
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-4.79
|
-0.67
|
-1.41
|
| Research and Development Expenses |
$281.41 M
|
$210.76 M
|
$142.76 M
|
$121.31 M
|
$45.20 M
|
$11.04 M
|
$4.28 M
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$62.48 M
|
$31.40 M
|
$28.20 M
|
$28.72 M
|
$13.45 M
|
$2.79 M
|
$517,000.00
|
$189.00 M
|
$161.00 M
|
$128.00 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$62.48 M
|
$31.40 M
|
$28.20 M
|
$28.72 M
|
$13.45 M
|
$2.79 M
|
$517,000.00
|
$189.00 M
|
$161.00 M
|
$128.00 M
|
| Other Expenses |
$0.00
|
$0.00
|
$2.86 M
|
-$8,000.00
|
-$790,000.00
|
-$1.32 M
|
-$21,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$343.89 M
|
$242.16 M
|
$170.96 M
|
$150.03 M
|
$58.65 M
|
$13.83 M
|
$4.80 M
|
$189.00 M
|
$161.00 M
|
$128.00 M
|
| Cost And Expenses |
$0.00
|
$242.16 M
|
$170.96 M
|
$150.03 M
|
$58.65 M
|
$13.83 M
|
$4.80 M
|
$3.12 B
|
$2.44 B
|
$2.16 B
|
| Interest Income |
$26.92 M
|
$7.64 M
|
$2.92 M
|
$742,000.00
|
$56,000.00
|
$290,000.00
|
$5,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$2.92 M
|
$0.00
|
$396,000.00
|
$0.00
|
$5,000.00
|
$616.00 M
|
$625.00 M
|
$546.00 M
|
| Depreciation & Amortization |
$0.00
|
$2.46 M
|
$3.35 M
|
$1.09 M
|
$700,000.00
|
$271,000.00
|
$24,000.00
|
$867.00 M
|
$766.00 M
|
$614.00 M
|
| EBITDA |
-$343.89 M |
-$233.48 M |
-$164.75 M |
-$148.20 M |
-$58.34 M |
-$14.59 M |
-$4.79 M |
$949.00 M |
$106.00 M |
$736.00 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1.88
|
0.08
|
0.87
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-0.81
|
-0.47
|
0.08
|
| Total Other Income/Expenses Net |
$26.47 M
|
$6.23 M
|
$2.86 M
|
$734,000.00
|
-$790,000.00
|
-$1.03 M
|
-$16,000.00
|
-$126.00 M
|
-$649.00 M
|
-$491.00 M
|
| Income Before Tax |
-$317.42 M
|
-$235.94 M
|
-$168.10 M
|
-$149.29 M
|
-$59.44 M
|
-$14.86 M
|
-$4.81 M
|
-$538.00 M
|
-$1.29 B
|
-$427.00 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-1.06
|
-0.94
|
-0.51
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$2.86 M
|
-$8,000.00
|
-$700,000.00
|
-$1.32 M
|
-$11,000.00
|
-$610.00 M
|
-$45.00 M
|
-$474.00 M
|
| Net Income |
-$317.42 M
|
-$235.94 M
|
-$165.24 M
|
-$149.28 M
|
-$58.74 M
|
-$13.54 M
|
-$4.81 M
|
$76.00 M
|
-$1.24 B
|
$50.00 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.15
|
-0.91
|
0.06
|
| EPS |
-3.37 |
-3.95 |
-3.18 |
-2.93 |
-4.08 |
-0.3 |
-0.47 |
0.47 |
-9.61 |
0.4 |
| EPS Diluted |
-3.37 |
-3.95 |
-3.18 |
-2.93 |
-4.08 |
-0.3 |
-0.47 |
0.47 |
-9.61 |
0.4 |
| Weighted Average Shares Out |
$94.14 M
|
$59.68 M
|
$51.98 M
|
$50.90 M
|
$14.40 M
|
$45.42 M
|
$10.32 M
|
$162.00 M
|
$129.00 M
|
$125.00 M
|
| Weighted Average Shares Out Diluted |
$94.14 M
|
$59.68 M
|
$51.98 M
|
$50.90 M
|
$14.40 M
|
$45.42 M
|
$10.32 M
|
$162.00 M
|
$129.00 M
|
$126.00 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
